Eupraxia Pharmaceuticals Files May 2025 Report
Ticker: EPRX · Form: 6-K · Filed: Jun 2, 2025 · CIK: 1581178
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing
TL;DR
Eupraxia Pharma dropped its May 6-K with shareholder meeting docs. Check the proxy.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 30, 2025, reporting on activities for the month of May 2025. The filing includes a Management Information Circular, Notice of Annual General and Special Meeting of Shareholders, and a Form of Proxy. The company is incorporated in Canada and its fiscal year ends on December 31.
Why It Matters
This filing provides shareholders with important information regarding the company's upcoming annual general meeting and related governance documents.
Risk Assessment
Risk Level: low — This filing is routine administrative and shareholder communication, not indicating new financial or operational risks.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- May 2025 (date) — Reporting period
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (address) — Principal executive office
- 001-41923 (company_id) — Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed for the month of May 2025 and includes a Management Information Circular, Notice of Annual General and Special Meeting of Shareholders, and a Form of Proxy.
What is Eupraxia Pharmaceuticals Inc.'s principal executive office address?
The principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
What is the Commission File Number for Eupraxia Pharmaceuticals Inc.?
The Commission File Number is 001-41923.
Does Eupraxia Pharmaceuticals Inc. file annual reports under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals Inc. files annual reports under Form 40-F.
When is Eupraxia Pharmaceuticals Inc.'s fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 2, 2025 regarding EUPRAXIA PHARMACEUTICALS INC. (EPRX).